Request Appointment
Moffitt Cancer Center12902 USF Magnolia DrTampa, FL 33612
Fax+1 404-778-2177
Overview of Dr. Tarhini
Dr. Ahmad Tarhini is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Kaunas Medical Institute and has been in practice 27 years. Dr. Tarhini accepts several types of health insurance, listed below. He is one of 200 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2003 - 2006- UPMC Medical EducationResidency, Internal Medicine, 2000 - 2003
Kaunas Medical InstituteClass of 1999
Certifications & Licensure
FL State Medical License 2019 - 2027
GA State Medical License 2018 - 2020
OH State Medical License 2017 - 2019
PA State Medical License 2001 - 2018
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2015-2016
Clinical Trials
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2006 Oct 01
- VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Jun 01
- Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2008 Oct 01
Publications & Presentations
PubMed
- Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma.Ahmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, Sandra J Lee, F Stephen Hodi
Melanoma Research. 2026-06-01 - Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab.Mohammad Ali Khaksar, Islam Eljilany, Ibrahim Yassine, Xiaoqing Yu, Jamie K Teer
Journal of Clinical Medicine. 2026-03-19 - Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.Vaseem M Khatri, Michael Aboujaoude, Lilit Karapetyan, Ahmad A Tarhini, Andrew S Brohl
Journal of Neuro-Oncology. 2026-03-09
Journal Articles
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaIgor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Lectures
- United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.2019 ASCO Annual Meeting - 6/1/2019
- Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Association of Community Cancer Centers(ACCC) 30th National ConferenceAssociation of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
Authored Content
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Press Mentions
Moffitt to Unveil Plenary and Late-Breaking Findings on Blood, Melanoma, and Brain Metastases at ASCO 2025May 22nd, 2025- Estimating Complex Immune Cell Structures by AI Tools for Survival Prediction in Advanced MelanomaApril 25th, 2025
- AI-Powered Analysis of Immune Cell Complexity Enhances Survival Predictions in Advanced MelanomaApril 24th, 2025
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Oklahoma
First Choice
First Health PPO
Great West PPOHealth Net Oregon PPO
HealthAmerica HealthAssurance PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
